Bacognize®
Research
Bacognize®
Research
Don’t see what you’re looking for? All additional research is categorized under supportive research.
Safety evaluation of the genotoxicity and subchronic toxicity of standardized bacopa extract (Bacognize®) from Bacopa monnieri.
Muchhara J et al.
Toxicol Res Applicat. 2023 Feb. 7: 1-17. doi: 10.1177/23978473231162859
The no-observed-adverse-effect level (NOAEL) for Bacognize® was established based on the subchronic study and was determined as at least 1000 mg/kg bw/day. These results indicate that Bacognize® does not cause significant adverse effects and suggest its tolerability up to 1000 mg/kg (highest dose tested) for the daily administration of 90 days.
Effects of a Bacopa monnieri extract (Bacognize®) on stress, fatigue, quality of life and sleep in adults with self-reported poor sleep: A randomised, double-blind, placebo-controlled study.
Lopresti AL et al.
J Funct Foods. Oct 2021. 85: 104671. Epub 05 Aug 2021. doi: 10.1016/j.jff.2021.104671
Researchers examined the ability of Bacognize® to act as an adaptogen. Quality of life (QOL) measures were taken as well as salivary biomarkers. The results showed an overall improvement in the Bacognize® group when compared to placebo in all QOL measures (alertness upon awakening, emotional wellbeing, general health and pain), with positive changes in PM melatonin, decrease in CRP, and trending increase of morning cortisol levels. Overall, the quality of sleep was better based on the QOL measures, without the product inducing sleepiness or morning grogginess. The ability to improve grogginess was significant.
Acute effects of combined bacopa, American ginseng and whole coffee fruit on working memory and cerebral haemodynamic response of the prefrontal cortex: A double-blind, placebo-controlled study.
Best T et al.
Nutr Neurosci. 2019 Nov 18. 12pgs. doi: 10.1080/1028415X.2019.1690288
This study examined the acute effects on cognitive performance in healthy adults following intake of a combined, multi-ingredient supplement and also examined the effects on the prefrontal cortex. In addition to brain imaging, measures of mood and cognitive performance were assessed. Results of this multi-ingredient study further support those seen in previous studies examining Bacognize®.
Bacopa monnieri (Bacognize®) – Essential compliance to manage supply chain challenges.
Grime A et al.
Poster presentation in 7th Annual AHPA Botanical Congress. 2018 Nov. Las Vegas, NV, USA.
Market demand increases supply chain risk and without systematic supply chain criteria, several quality issues may arise. Multiple control points through a standardized supply chain regimen aim to offer quality assurance and control of a traditional Ayurvedic botanical commonly known to have supply chain concerns.
Development of a neuroprotective potential algorithm for medicinal plants.
Liu W et al.
University of Rhode Island. Neurochem Int. 2016 Sep 29. 100: 164-177.
As part of a strategy to help guide the selection and evaluation of medicinal plant candidates for their neuroprotective potential, researchers at the University of Rhode Island developed a Neuroprotective Potential Algorithm (NPA) by evaluating twenty-three standardized and chemically characterized Ayurvedic medicinal plant extracts in a panel of bioassays targeting oxidative stress, carbonyl stress, protein glycation, amyloid beta (Aβ) fibrillation, acetylcholinesterase (AChE) inhibition, and neuroinflammation.
Efficacy of standardized extract of Bacopa monnieri (Bacognize®) on cognitive functions of medical students: A six-week, randomized placebo-controlled trial.
Kumar et al.
Evidence-Based Comp Alter Med. 2016 Sep 15. Vol 2016 (Art ID 4103423): 8pgs. doi: 10.1155/2016/4103423
In a randomized, placebo-controlled crossover human clinical trial, administration of Bacognize® at 300mg/day to healthy medical students significantly improved (p<0.05) several parameters of cognitive function, including memory, focus, and attention. No adverse events were reported in either the Bacognize® or placebo groups.
Effects of Bacopa monnieri (Bacognize®) on memory and cognitive function in healthy older adults: A double-blind placebo-controlled study.
Headapohl et al.
2012 Unpublished manuscript, pending poster presentation/publication.
In a randomized, placebo-controlled trial in older adults, positive trends in working memory, attention, and focus were seen in the Bacognize® group (300mg/day) compared to placebo. Further, no adverse events were reported in either the Bacognize or placebo groups.
Sustained cognitive effects and safety of HPLC-standardized Bacopa monnieri [Bacognize®] extract: A randomized, placebo controlled clinical trial.
Hingorani L et al.
Planta Med. 2012. 78-PH22. Poster presentation. doi: 10.1055/s-0032-1320681
In a randomized, placebo-controlled trial in older adults, significant improvement in the Bacognize® group (300mg/day) was seen over placebo in short-term memory, processing speed, attention, and depression. Additionally, an effect was observed four weeks after administration discontinued. No adverse events were reported in either the Bacognize® or placebo groups.
Effect of Bacopa monnieri [Bacognize®] on cognitive function in patients.
Goswami S et al.
Int J Collab Research Internal Med. 2011 May 10. 3(4): 285-293. ISSN: 1840-4529
Improvement in the Bacognize® group (300mg twice/day) was seen over placebo in areas of cognitive function in this six-month clinical trial conducted on geriatric patients. No adverse events were reported in either the Bacognize® or placebo groups.
Examining the nootropic effects of a special extract of Bacopa monniera on human cognitive functioning: 90 day double-blind placebo-controlled randomized trial.
Stough et al.
Phytother Res. 2008 Dec. 22(12): 1629-1634. doi: 10.1002/ptr.2537
Patients took 300mg of a Bacopa monnieri extract per day for 90 days or a placebo and underwent neuropsychological testing. It was shown that the extract significantly improved performance on the working memory factor and also reduced the number of false positives recorded in the Rapid Visual Information processing task.
Effects of a standardized Bacopa monnieri extract on cognitive performance, anxiety, and depression in the elderly: A randomized, double-blind, placebo-controlled trial.
Calabrese C et al.
J Altern Complement Med. 2008 Jul. 14(6): 707-713. doi: 10.1089/acm.2008.0018
Elderly patients without dementia took a standardized B. monnieri extract 300mg a day or a placebo for 12 weeks. Results showed that Bacopa participants had enhanced AVLT delayed word recall memory scores compared to placebo, as well as CESD-10 depression scores, combined state plus trait anxiety scores, and heart rate decreasing over time for the Bacopa group, while these measurements increased for the placebo group.
Pharmacology of Bacopa monnieri (Bacognize®) at 5HT1a and 5HT2a receptors.
Hall et al.
Am Soc Pharmacog Absts. 2005. 83-85. Poster presentation in 46th Am Soc Pharmacog (ASP) Annual Meeting, Corvallis, OR.
Pharmacology research on Bacognize® and its isolated constituents showed strong regulation at serotonin receptors that are key for higher cognitive functions such as memory, mood, and focus.
Bacopa monnieri: Monograph.
Altern Med Rev. Review. 2004 Mar. 9(1): 79-85.
A review over the Bacopa monniera, including a description, active constituents, mechanisms of action, clinical indications, and safety information. The topic mostly discussed is the improvements in cognitive function that the plant provides.
The chronic effects of an extract of Bacopa monnieri (Brahmi) on cognitive function in healthy human subjects.
Stough et al.
Psychopharmacology (Berl). 2001 Aug. 156(4): 481-4.
Patients took 300 mg of a B. monniera extract everyday for 12 weeks. Results showed that B. monniera significantly improved speed of visual information processing, learning rate, and memory consolidation measured by the AVLT, along with state anxiety being reduced, all compared to placebo. Maximal effects were evident after 12 weeks, which could indicate progressive rather than regressive positive effects over time.
Don’t see what you’re looking for? All additional research is categorized under supportive research.
Safety evaluation of the genotoxicity and subchronic toxicity of standardized bacopa extract (Bacognize®) from Bacopa monnieri.
Muchhara J et al.
Toxicol Res Applicat. 2023 Feb. 7: 1-17. doi: 10.1177/23978473231162859
The no-observed-adverse-effect level (NOAEL) for Bacognize® was established based on the subchronic study and was determined as at least 1000 mg/kg bw/day. These results indicate that Bacognize® does not cause significant adverse effects and suggest its tolerability up to 1000 mg/kg (highest dose tested) for the daily administration of 90 days.
Effects of a Bacopa monnieri extract (Bacognize®) on stress, fatigue, quality of life and sleep in adults with self-reported poor sleep: A randomised, double-blind, placebo-controlled study.
Lopresti AL et al.
J Funct Foods. Oct 2021. 85: 104671. Epub 05 Aug 2021. doi: 10.1016/j.jff.2021.104671
Researchers examined the ability of Bacognize® to act as an adaptogen. Quality of life (QOL) measures were taken as well as salivary biomarkers. The results showed an overall improvement in the Bacognize® group when compared to placebo in all QOL measures (alertness upon awakening, emotional wellbeing, general health and pain), with positive changes in PM melatonin, decrease in CRP, and trending increase of morning cortisol levels. Overall, the quality of sleep was better based on the QOL measures, without the product inducing sleepiness or morning grogginess. The ability to improve grogginess was significant.
Acute effects of combined bacopa, American ginseng and whole coffee fruit on working memory and cerebral haemodynamic response of the prefrontal cortex: A double-blind, placebo-controlled study.
Best T et al.
Nutr Neurosci. 2019 Nov 18. 12pgs. doi: 10.1080/1028415X.2019.1690288
This study examined the acute effects on cognitive performance in healthy adults following intake of a combined, multi-ingredient supplement and also examined the effects on the prefrontal cortex. In addition to brain imaging, measures of mood and cognitive performance were assessed. Results of this multi-ingredient study further support those seen in previous studies examining Bacognize®.
Bacopa monnieri (Bacognize®) – Essential compliance to manage supply chain challenges.
Grime A et al.
Poster presentation in 7th Annual AHPA Botanical Congress. 2018 Nov. Las Vegas, NV, USA.
Market demand increases supply chain risk and without systematic supply chain criteria, several quality issues may arise. Multiple control points through a standardized supply chain regimen aim to offer quality assurance and control of a traditional Ayurvedic botanical commonly known to have supply chain concerns.
Development of a neuroprotective potential algorithm for medicinal plants.
Liu W et al.
University of Rhode Island. Neurochem Int. 2016 Sep 29. 100: 164-177.
As part of a strategy to help guide the selection and evaluation of medicinal plant candidates for their neuroprotective potential, researchers at the University of Rhode Island developed a Neuroprotective Potential Algorithm (NPA) by evaluating twenty-three standardized and chemically characterized Ayurvedic medicinal plant extracts in a panel of bioassays targeting oxidative stress, carbonyl stress, protein glycation, amyloid beta (Aβ) fibrillation, acetylcholinesterase (AChE) inhibition, and neuroinflammation.
Efficacy of standardized extract of Bacopa monnieri (Bacognize®) on cognitive functions of medical students: A six-week, randomized placebo-controlled trial.
Kumar et al.
Evidence-Based Comp Alter Med. 2016 Sep 15. Vol 2016 (Art ID 4103423): 8pgs. doi: 10.1155/2016/4103423
In a randomized, placebo-controlled crossover human clinical trial, administration of Bacognize® at 300mg/day to healthy medical students significantly improved (p<0.05) several parameters of cognitive function, including memory, focus, and attention. No adverse events were reported in either the Bacognize® or placebo groups.
Effects of Bacopa monnieri (Bacognize®) on memory and cognitive function in healthy older adults: A double-blind placebo-controlled study.
Headapohl et al.
2012 Unpublished manuscript, pending poster presentation/publication.
In a randomized, placebo-controlled trial in older adults, positive trends in working memory, attention, and focus were seen in the Bacognize® group (300mg/day) compared to placebo. Further, no adverse events were reported in either the Bacognize or placebo groups.
Sustained cognitive effects and safety of HPLC-standardized Bacopa monnieri [Bacognize®] extract: A randomized, placebo controlled clinical trial.
Hingorani L et al.
Planta Med. 2012. 78-PH22. Poster presentation. doi: 10.1055/s-0032-1320681
In a randomized, placebo-controlled trial in older adults, significant improvement in the Bacognize® group (300mg/day) was seen over placebo in short-term memory, processing speed, attention, and depression. Additionally, an effect was observed four weeks after administration discontinued. No adverse events were reported in either the Bacognize® or placebo groups.
Effect of Bacopa monnieri [Bacognize®] on cognitive function in patients.
Goswami S et al.
Int J Collab Research Internal Med. 2011 May 10. 3(4): 285-293. ISSN: 1840-4529
Improvement in the Bacognize® group (300mg twice/day) was seen over placebo in areas of cognitive function in this six-month clinical trial conducted on geriatric patients. No adverse events were reported in either the Bacognize® or placebo groups.
Examining the nootropic effects of a special extract of Bacopa monniera on human cognitive functioning: 90 day double-blind placebo-controlled randomized trial.
Stough et al.
Phytother Res. 2008 Dec. 22(12): 1629-1634. doi: 10.1002/ptr.2537
Patients took 300mg of a Bacopa monnieri extract per day for 90 days or a placebo and underwent neuropsychological testing. It was shown that the extract significantly improved performance on the working memory factor and also reduced the number of false positives recorded in the Rapid Visual Information processing task.
Effects of a standardized Bacopa monnieri extract on cognitive performance, anxiety, and depression in the elderly: A randomized, double-blind, placebo-controlled trial.
Calabrese C et al.
J Altern Complement Med. 2008 Jul. 14(6): 707-713. doi: 10.1089/acm.2008.0018
Elderly patients without dementia took a standardized B. monnieri extract 300mg a day or a placebo for 12 weeks. Results showed that Bacopa participants had enhanced AVLT delayed word recall memory scores compared to placebo, as well as CESD-10 depression scores, combined state plus trait anxiety scores, and heart rate decreasing over time for the Bacopa group, while these measurements increased for the placebo group.
Pharmacology of Bacopa monnieri (Bacognize®) at 5HT1a and 5HT2a receptors.
Hall et al.
Am Soc Pharmacog Absts. 2005. 83-85. Poster presentation in 46th Am Soc Pharmacog (ASP) Annual Meeting, Corvallis, OR.
Pharmacology research on Bacognize® and its isolated constituents showed strong regulation at serotonin receptors that are key for higher cognitive functions such as memory, mood, and focus.
Bacopa monnieri: Monograph.
Altern Med Rev. Review. 2004 Mar. 9(1): 79-85.
A review over the Bacopa monniera, including a description, active constituents, mechanisms of action, clinical indications, and safety information. The topic mostly discussed is the improvements in cognitive function that the plant provides.
The chronic effects of an extract of Bacopa monnieri (Brahmi) on cognitive function in healthy human subjects.
Stough et al.
Psychopharmacology (Berl). 2001 Aug. 156(4): 481-4.
Patients took 300 mg of a B. monniera extract everyday for 12 weeks. Results showed that B. monniera significantly improved speed of visual information processing, learning rate, and memory consolidation measured by the AVLT, along with state anxiety being reduced, all compared to placebo. Maximal effects were evident after 12 weeks, which could indicate progressive rather than regressive positive effects over time.
